Business Description
Armata Pharmaceuticals Inc
NAICS : 325414
SIC : 2836
4503 Glencoe Avenue, Marina del Rey, CA, USA, 90292
Description
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Further, the company is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.21 | |||||
| Equity-to-Asset | 0.57 | |||||
| Debt-to-Equity | 0.63 | |||||
| Debt-to-EBITDA | -1.52 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -1.1 | |||||
| Beneish M-Score | 29.22 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 50.5 | |||||
| 3-Year EPS without NRI Growth Rate | 52.5 | |||||
| 3-Year FCF Growth Rate | 47 | |||||
| 3-Year Book Growth Rate | -36.6 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 66.7 | |||||
| 9-Day RSI | 60.47 | |||||
| 14-Day RSI | 56.74 | |||||
| 6-1 Month Momentum % | -29.52 | |||||
| 12-1 Month Momentum % | -4.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.82 | |||||
| Quick Ratio | 7.82 | |||||
| Cash Ratio | 7.45 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -127.4 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -2325.51 | |||||
| Net Margin % | -2263.18 | |||||
| ROE % | -76.26 | |||||
| ROA % | -41.13 | |||||
| ROIC % | -63.07 | |||||
| ROC (Joel Greenblatt) % | -116.01 | |||||
| ROCE % | -44.93 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 90.42 | |||||
| PB Ratio | 2.49 | |||||
| Price-to-Tangible-Book | 3.22 | |||||
| EV-to-EBIT | -5.49 | |||||
| EV-to-Forward-EBIT | -3.57 | |||||
| EV-to-EBITDA | -5.73 | |||||
| EV-to-Forward-EBITDA | -3.57 | |||||
| EV-to-Revenue | 124.34 | |||||
| EV-to-Forward-Revenue | 37.91 | |||||
| EV-to-FCF | -6.3 | |||||
| Price-to-Net-Current-Asset-Value | 60.71 | |||||
| Price-to-Net-Cash | 425 | |||||
| Earnings Yield (Greenblatt) % | -18.2 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with AMEX:ARMP
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.168 | ||
| EPS (TTM) ($) | -1 | ||
| Beta | 0.04 | ||
| Volatility % | 63.17 | ||
| 14-Day RSI | 56.74 | ||
| 14-Day ATR ($) | 0.2572 | ||
| 20-Day SMA ($) | 4.079005 | ||
| 12-1 Month Momentum % | -4.39 | ||
| 52-Week Range ($) | 2.82 - 6.49 | ||
| Shares Outstanding (Mil) | 36.11 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Armata Pharmaceuticals Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||